Natashia Harasym

1.3k total citations
14 papers, 1.1k citations indexed

About

Natashia Harasym is a scholar working on Biomaterials, Molecular Biology and Oncology. According to data from OpenAlex, Natashia Harasym has authored 14 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Biomaterials, 8 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Natashia Harasym's work include Nanoparticle-Based Drug Delivery (9 papers), Cancer therapeutics and mechanisms (4 papers) and Microtubule and mitosis dynamics (4 papers). Natashia Harasym is often cited by papers focused on Nanoparticle-Based Drug Delivery (9 papers), Cancer therapeutics and mechanisms (4 papers) and Microtubule and mitosis dynamics (4 papers). Natashia Harasym collaborates with scholars based in Canada, United States and Netherlands. Natashia Harasym's co-authors include Lawrence D. Mayer, Paul Tardi, Sharon A. Johnstone, Troy O. Harasym, Marcel B. Bally, Pierrot Harvie, David Bermudes, Sherwin Xie, Euan C. Ramsay and Natalia Zisman and has published in prestigious journals such as PLoS ONE, Cancer Research and Clinical Cancer Research.

In The Last Decade

Natashia Harasym

14 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Natashia Harasym Canada 10 610 564 329 213 174 14 1.1k
Eric A. Forssen United States 10 579 0.9× 500 0.9× 198 0.6× 332 1.6× 59 0.3× 10 1.1k
J. Margison United Kingdom 13 351 0.6× 335 0.6× 178 0.5× 190 0.9× 37 0.2× 16 841
Grzegorz Pietrzyński Poland 9 415 0.7× 446 0.8× 190 0.6× 148 0.7× 28 0.2× 15 910
Dawn Waterhouse Canada 20 568 0.9× 704 1.2× 360 1.1× 308 1.4× 21 0.1× 36 1.4k
S S Burtles United Kingdom 12 541 0.9× 408 0.7× 304 0.9× 185 0.9× 27 0.2× 17 1.1k
Erin Joseph United States 17 242 0.4× 584 1.0× 169 0.5× 228 1.1× 37 0.2× 31 985
Seung Woo Chung South Korea 20 270 0.4× 493 0.9× 290 0.9× 257 1.2× 30 0.2× 47 1.0k
Nancy L. Boman Canada 9 326 0.5× 399 0.7× 101 0.3× 122 0.6× 27 0.2× 10 692
Jennifer I. Hare United Kingdom 9 737 1.2× 417 0.7× 585 1.8× 144 0.7× 16 0.1× 12 1.2k
Kazunori Toma Japan 21 219 0.4× 698 1.2× 114 0.3× 59 0.3× 145 0.8× 64 1.2k

Countries citing papers authored by Natashia Harasym

Since Specialization
Citations

This map shows the geographic impact of Natashia Harasym's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natashia Harasym with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natashia Harasym more than expected).

Fields of papers citing papers by Natashia Harasym

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natashia Harasym. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natashia Harasym. The network helps show where Natashia Harasym may publish in the future.

Co-authorship network of co-authors of Natashia Harasym

This figure shows the co-authorship network connecting the top 25 collaborators of Natashia Harasym. A scholar is included among the top collaborators of Natashia Harasym based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natashia Harasym. Natashia Harasym is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Waterhouse, Dawn, Brent W. Sutherland, Nancy Dos Santos, et al.. (2014). Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities. Investigational New Drugs. 32(6). 1071–1082. 12 indexed citations
2.
Hare, Jennifer I., Malathi Anantha, Nancy Dos Santos, et al.. (2013). Treatment of Colorectal Cancer Using a Combination of Liposomal Irinotecan (Irinophore C™) and 5-Fluorouracil. PLoS ONE. 8(4). e62349–e62349. 26 indexed citations
3.
Zhigaltsev, Igor V., Jason Crawford, Lawrence N. Amankwa, et al.. (2010). Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. Journal of Controlled Release. 144(3). 332–340. 77 indexed citations
4.
Ansell, Steven M., Sharon A. Johnstone, Paul Tardi, et al.. (2008). Development of highly efficacious hydrophobic paclitaxel prodrugs delivered in nanoparticles for fixed-ratio drug combination applications. Cancer Research. 68. 5734–5734. 3 indexed citations
5.
Tardi, Paul, Sharon A. Johnstone, Natashia Harasym, et al.. (2008). In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leukemia Research. 33(1). 129–139. 288 indexed citations
6.
Ansell, Steven M., Sharon A. Johnstone, Paul Tardi, et al.. (2008). Modulating the Therapeutic Activity of Nanoparticle Delivered Paclitaxel by Manipulating the Hydrophobicity of Prodrug Conjugates. Journal of Medicinal Chemistry. 51(11). 3288–3296. 110 indexed citations
7.
Webb, Murray S., Sharon A. Johnstone, Ryan Gallagher, et al.. (2006). In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. European Journal of Pharmaceutics and Biopharmaceutics. 65(3). 289–299. 29 indexed citations
8.
Tardi, Paul, Ryan Gallagher, Sharon A. Johnstone, et al.. (2006). Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1768(3). 678–687. 110 indexed citations
9.
Mayer, Lawrence D., Troy O. Harasym, Paul Tardi, et al.. (2006). Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Molecular Cancer Therapeutics. 5(7). 1854–1863. 276 indexed citations
10.
Harasym, Troy O., Paul Tardi, Natashia Harasym, et al.. (2006). Increased Preclinical Efficacy of Irinotecan and Floxuridine Coencapsulated Inside Liposomes Is Associated With Tumor Delivery of Synergistic Drug Ratios. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 16(8). 361–374. 66 indexed citations
11.
Johnstone, Sharon A., Pierrot Harvie, Salam Kadhim, et al.. (2005). Synergistic antitumor activity observed for a fixed ratio liposome formulation of Cytarabine (Cyt):Daunorubicin (Daun) against preclinical leukemia models. Cancer Research. 65. 329–329. 3 indexed citations
12.
Mayer, Lawrence D., Troy O. Harasym, Natashia Harasym, et al.. (2004). A pharmaceutical approach to achieve synergy in vivo: A fixed ratio formulation of Irinotecan and Floxuridine for treatment of colorectal cancer. Cancer Research. 64. 126–127. 2 indexed citations
13.
Ramsay, Euan C., Dawn Waterhouse, Natashia Harasym, et al.. (2004). Liposomal Irinotecan. Clinical Cancer Research. 10(19). 6638–6649. 70 indexed citations
14.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eric A. Forssen Breakdown of academic impact, for papers by J. Margison Breakdown of academic impact, for papers by Grzegorz Pietrzyński Breakdown of academic impact, for papers by Dawn Waterhouse Breakdown of academic impact, for papers by S S Burtles Breakdown of academic impact, for papers by Erin Joseph Breakdown of academic impact, for papers by Seung Woo Chung Breakdown of academic impact, for papers by Nancy L. Boman Breakdown of academic impact, for papers by Jennifer I. Hare Breakdown of academic impact, for papers by Kazunori Toma
Rankless by CCL
2026